Linked Life Data

1546123

Source:http://linkedlifedata.com/resource/pubmed/id/1546123

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1992-4-15
pubmed:abstractText
A randomized, double-blind, multicentre study was performed to compare the effects of moclobemide and amineptine in the treatment of endogenous depression in out-patients. Ninety patients received moclobemide, 450 mg/day and 94 received amineptine 200 mg/day in two parallel groups, over a trial period of 8 weeks. At the end of 4 weeks doses could be reduced to 300 mg/day, moclobemide and 100 mg/day, amineptine if required. All evaluated patients showed a significant clinical improvement during treatment, but no significant difference occurred between the groups. When patients were asked to assess the benefit of their treatment, 76% thought their condition had improved following moclobemide therapy, compared to 53% of those receiving amineptine. Both drugs were well tolerated, and over 60% of patients reported no side-effects. Moclobemide appeared to be as effective as amineptine in the treatment of these patients, and was significantly better tolerated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0033-3158
pubmed:author
pubmed:issnType
Print
pubmed:volume
106 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S116-7
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients.
pubmed:affiliation
CHS Rouffach, France.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Multicenter Study